Genome-wide DNA methylation profiling integrated with gene expression profiling identifies PAX9 as a novel prognostic marker in chronic lymphocytic leukemia

In chronic lymphocytic leukemia (CLL), epigenomic and genomic studies have expanded the existing knowledge about the disease biology and led to the identification of potential biomarkers relevant for implementation of personalized medicine. In this study, an attempt has been made to examine and inte...

Full description

Saved in:
Bibliographic Details
Published in:Clinical epigenetics 2017-05, Vol.9 (1), p.57-57, Article 57
Main Authors: Rani, Lata, Mathur, Nitin, Gupta, Ritu, Gogia, Ajay, Kaur, Gurvinder, Dhanjal, Jaspreet Kaur, Sundar, Durai, Kumar, Lalit, Sharma, Atul
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - genetics
CD19 antigen
Chronic lymphocytic leukemia
Circadian rhythm
Cryptochromes - genetics
DNA fingerprinting
DNA Methylation
Epigenesis, Genetic
Epigenomics - methods
Female
Gene expression
Gene Expression Profiling - methods
Gene Expression Regulation, Leukemic
Genomes
Humans
Integration
Kinases
Leukemia, Lymphocytic, Chronic, B-Cell - genetics
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Lymphatic leukemia
Lymphocytes B
Male
Middle Aged
Mutation
Neoplasm Staging
PAX9
PAX9 Transcription Factor - genetics
Polymerase chain reaction
Precision medicine
Prognosis
Promoter methylation
Survival Analysis
Transcription factors
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In chronic lymphocytic leukemia (CLL), epigenomic and genomic studies have expanded the existing knowledge about the disease biology and led to the identification of potential biomarkers relevant for implementation of personalized medicine. In this study, an attempt has been made to examine and integrate the global DNA methylation changes with gene expression profile and their impact on clinical outcome in early stage CLL patients. The integration of DNA methylation profile (  = 14) with the gene expression profile (  = 21) revealed 142 genes as hypermethylated-downregulated and; 62 genes as hypomethylated-upregulated in early stage CLL patients compared to CD19+ B-cells from healthy individuals. The mRNA expression levels of 17 genes identified to be differentially methylated and/or differentially expressed was further examined in early stage CLL patients (  = 93) by quantitative real time PCR (RQ-PCR). Significant differences were observed in the mRNA expression of , , , , , , and genes in CLL cells as compared to B-cells from healthy individuals. The analysis in the mutation based categories (Unmutated = 39, Mutated = 54) revealed significantly higher mRNA expression of and genes in the unmutated subgroup (  
ISSN:1868-7075
1868-7083
1868-7083
1868-7075
DOI:10.1186/s13148-017-0356-0